Abstract
High-grade nodal lymphomas (HGNL) in dogs are aggressive malignancies and important comparative models for human non-Hodgkin lymphoma; however, their copy-number architecture has not been completely defined. This study applied high‑density SNP arrays optimized for FFPE DNA to 90 canine HGNLs (77 B‑cell [BCL], 13 T‑cell [TCL]) to map genome‑wide copy-number alterations (CNAs) and recurrent copy-number altered regions (CNARs), and to link them with candidate gene drivers and potential therapeutic targets. Across immunophenotypes, CNAs were dominated by gains on CFA13, syntenic to human 8q24, encompassing MYC and other oncogenes, supporting conserved MYC‑driven programs in aggressive lymphoma. BCLs exhibited a markedly higher CNA burden and broader CNAR coverage (~24% of the genome) than TCLs (6.8%), whereas TCL CNARs were fewer and shorter, consistent with reliance on a limited set of highly impactful lesions rather than widespread chromosomal instability. CNAR analysis increased sensitivity for shared loci and revealed genomic divergence between BCLs and TCLs with limited regional overlap. Integration of CNAR genes with human DepMap dependency data and DGIdb identified eight druggable genes linked to 17 antineoplastic agents, nominating both repurposable drugs already used in canine lymphoma and new candidates (e.g., proteasome and HDAC inhibitors, pathway modulators) for biomarker‑guided trials. These findings define distinct yet partially convergent copy‑number architectures in canine B‑ and T‑cell HGNL, refine the catalogue of recurrent lesions, and uncover multiple actionable genomic alterations, reinforcing spontaneous canine lymphoma as a robust translational platform for precision oncology.